Tanya Lewis
Director/Board Member bei DIAMEDICA THERAPEUTICS INC.
Vermögen: 1 Mio $ am 31.03.2024
Profil
Tanya N.
Lewis is an Independent Director at DiaMedica Therapeutics, Inc. She previously held positions as a Senior Director-Regulatory Affairs at Millennium Pharmaceuticals, Inc., a Director at Replimune Group, Inc., a VP-Regulatory Affairs & Quality Assurance at Idera Pharmaceuticals, Inc., Tesaro, Inc., and Seaside Therapeutics LLC, a Senior Vice President-Regulatory Affairs at Karyopharm Therapeutics, Inc., and a Vice President-Regulatory & Quality Affairs at Syros Pharmaceuticals, Inc. She is currently serving as the Chief Development Operations Officer at Replimune Group, Inc. Ms. Lewis received a graduate degree from Massachusetts College of Pharmacy & Health Science and an undergraduate degree from Northeastern University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
REPLIMUNE GROUP, INC.
0,22% | 13.06.2023 | 135 293 ( 0,22% ) | 1 Mio $ | 31.03.2024 |
| 25.03.2024 | 0 ( -.--% ) | - $ | 31.03.2024 |
Aktive Positionen von Tanya Lewis
| Unternehmen | Position | Beginn |
|---|---|---|
| DIAMEDICA THERAPEUTICS INC. | Director/Board Member | 01.03.2023 |
Ehemalige bekannte Positionen von Tanya Lewis
| Unternehmen | Position | Ende |
|---|---|---|
| REPLIMUNE GROUP, INC. | Corporate Officer/Principal | 01.04.2024 |
| REPLIMUNE GROUP, INC. | Director/Board Member | 07.05.2021 |
| SYROS PHARMACEUTICALS, INC. | General Counsel | 01.07.2018 |
Idera Pharmaceuticals, Inc.
 Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. | General Counsel | 01.12.2016 |
| TESARO INC | General Counsel | 01.01.2015 |
Ausbildung von Tanya Lewis
| Massachusetts College of Pharmacy & Health Science | Graduate Degree |
| Northeastern University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 4 |
|---|---|
| DIAMEDICA THERAPEUTICS INC. | Health Technology |
| KARYOPHARM THERAPEUTICS INC. | Health Technology |
| SYROS PHARMACEUTICALS, INC. | Health Technology |
| REPLIMUNE GROUP, INC. | Health Technology |
| Private Unternehmen | 5 |
|---|---|
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. | Health Technology |
Vion Pharmaceuticals, Inc.
 Vion Pharmaceuticals, Inc. BiotechnologyHealth Technology Vion Pharmaceuticals, Inc. develops therapeutics for the treatment of cancer. The company was founded in March 1992 and is headquartered in New Haven, CT. | Health Technology |
Tesaro, Inc.
 Tesaro, Inc. Pharmaceuticals: MajorHealth Technology TESARO, Inc. is an oncology-focused biopharmaceutical company, which engages in the research and development of biopharmaceutical products. The firm offers Niraparib products. The company was founded by Leon Oliver Moulder, Jr., Mary Lynne Hedley, and Richard J. Rodgers on March 26, 2010 and is headquartered in Waltham, MA. | Health Technology |
Seaside Therapeutics LLC
 Seaside Therapeutics LLC Medical DistributorsDistribution Services Seaside Therapeutics LLC engages in the development of drug treatments to correct or improve the course of autism, fragile X syndrome and other neurodevelopmental disorders. Its products include STX209, STX107, and STX110. The company was founded by Randall L. Carpenter and Mark F. Bear in 2005 and is headquartered in Cambridge, MA. | Distribution Services |
